Addison D, Branch M, Baik AH, Fradley MG, Okwuosa T, Reding KW, Simpson KE, Suero-Abreu GA, Yang EH, Yancy CW (2023) Equity in cardio-oncology care and research: a scientific statement from the American Heart Association. Circulation 148:297–308. https://doi.org/10.1161/CIR.0000000000001158

Article  PubMed  Google Scholar 

Afanasyeva M, Georgakopoulos D, Rose NR (2004) Autoimmune myocarditis: cellular mediators of cardiac dysfunction. Autoimmun Rev 3:476–486. https://doi.org/10.1016/j.autrev.2004.08.009

Article  CAS  PubMed  Google Scholar 

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72. https://doi.org/10.1186/s40425-016-0177-2

Article  PubMed  PubMed Central  Google Scholar 

Alturki NA (2023) Review of the immune checkpoint inhibitors in the context of cancer treatment. J Clin Med 12:4301. https://doi.org/10.3390/jcm12134301

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andres MS, Ramalingam S, Rosen SD, Baksi J, Khattar R, Kirichenko Y, Young K, Yousaf N, Okines A, Huddart R, Harrington K, Furness AJS, Turajlic S, Pickering L, Popat S, Larkin J, Lyon AR (2022) The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: including myocarditis and the new entity of non inflammatory left ventricular dysfunction. Cardio-Oncol Lond Engl 8:21. https://doi.org/10.1186/s40959-022-00147-w

Article  Google Scholar 

Andrews LP, Marciscano AE, Drake CG, Vignali DAA (2017) LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 276:80–96. https://doi.org/10.1111/imr.12519

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arana Y, Gálvez RI, Jacobs T (2022) Role of the PD-1/PD-L1 pathway in experimental Trypanosoma cruzi infection and potential therapeutic options. Front Immunol 13:866120. https://doi.org/10.3389/fimmu.2022.866120

Article  CAS  PubMed  PubMed Central  Google Scholar 

Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X, Tannous E, Zhang Y, Sugiura A, Taylor BC, Hanna A, Zhang S, Amancherla K, Tai W, Wright JJ, Wei SC, Opalenik SR, Toren AL, Rathmell JC, Ferrell PB, Phillips EJ, Mallal S, Johnson DB, Allison JP, Moslehi JJ, Balko JM (2022) T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature 611:818–826. https://doi.org/10.1038/s41586-022-05432-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bockstahler M, Fischer A, Goetzke CC, Neumaier HL, Sauter M, Kespohl M, Müller A-M, Meckes C, Salbach C, Schenk M, Heuser A, Landmesser U, Weiner J, Meder B, Lehmann L, Kratzer A, Klingel K, Katus HA, Kaya Z, Beling A (2020) Heart-specific immune responses in an animal model of autoimmune-related myocarditis mitigated by an immunoproteasome inhibitor and genetic ablation. Circulation 141:1885–1902. https://doi.org/10.1161/CIRCULATIONAHA.119.043171

Article  CAS  PubMed  Google Scholar 

Bu D, Tarrio M, Maganto-Garcia E, Stavrakis G, Tajima G, Lederer J, Jarolim P, Freeman GJ, Sharpe AH, Lichtman AH (2011) Impairment of the PD-1 pathway increases atherosclerotic lesion development and inflammation. Arterioscler Thromb Vasc Biol 31:1100–1107. https://doi.org/10.1161/ATVBAHA.111.224709

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cochain C, Chaudhari SM, Koch M, Wiendl H, Eckstein H-H, Zernecke A (2014) Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. PLoS ONE 9:e93280. https://doi.org/10.1371/journal.pone.0093280

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA (2020) Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer 8:e001361. https://doi.org/10.1136/jitc-2020-001361

Article  PubMed  PubMed Central  Google Scholar 

Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, Peeters M, Vulsteke C (2021) Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open 6:100216. https://doi.org/10.1016/j.esmoop.2021.100216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dolladille C, Akroun J, Morice P-M, Dompmartin A, Ezine E, Sassier M, Da-Silva A, Plane A-F, Legallois D, L’Orphelin J-M, Alexandre J (2021) Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 42:4964–4977. https://doi.org/10.1093/eurheartj/ehab618

Article  CAS  PubMed  Google Scholar 

Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, Mosarla RC, Lee C, Zlotoff DA, Raghu VK, Hartmann SE, Gilman HK, Gong J, Zubiri L, Sullivan RJ, Reynolds KL, Mayrhofer T, Zhang L, Hoffmann U, Neilan TG (2020) Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation 142:2299–2311. https://doi.org/10.1161/CIRCULATIONAHA.120.049981

Article  CAS  PubMed  PubMed Central  Google Scholar 

D’Souza M, Nielsen D, Svane IM, Iversen K, Rasmussen PV, Madelaire C, Fosbøl E, Køber L, Gustafsson F, Andersson C, Gislason G, Torp-Pedersen C, Schou M (2021) The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 42:1621–1631. https://doi.org/10.1093/eurheartj/ehaa884

Article  PubMed  Google Scholar 

Du S, Zhou L, Alexander GS, Park K, Yang L, Wang N, Zaorsky NG, Ma X, Wang Y, Dicker AP, Lu B (2018) PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol 13:510–520. https://doi.org/10.1016/j.jtho.2017.12.002

Article  CAS  PubMed  Google Scholar 

Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJA, Hobo W, Gorecka MA, de Haan AFJ, Mulders P, Punt CJA, Jacobs JFM, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM (2012) PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother 35:169. https://doi.org/10.1097/CJI.0b013e318247a4e7

Article  CAS  PubMed  Google Scholar 

Efentakis P, Choustoulaki A, Kostopoulos Ι, Varela A, Georgoulis A, Tsekenis G, Gakiopoulou C, Ntanasis-Stathopoulos I, Davos C, Tsitsiloni O, Dimopoulos MA, Terpos E, Gavriatopoulou M, Andreadou I (2023) Establishment of an in vivo murine model of immune checkPoint inhibitors cardiotoxicity: emerging role of vascular permeability in pembrolizumab-induced cardiotoxicity. Eur Heart J 44(ehad655):770. https://doi.org/10.1093/eurheartj/ehad655.770

Article  Google Scholar 

Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chłopicki S, Gavriatopoulou M, Andreadou I (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01046-0

Article  PubMed  Google Scholar 

Ewing MM, Karper JC, Abdul S, de Jong RCM, Peters HAB, de Vries MR, Redeker A, Kuiper J, Toes REM, Arens R, Jukema JW, Quax PHA (2013) T-cell co-stimulation by CD28–CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol 168:1965–1974. https://doi.org/10.1016/j.ijcard.2012.12.085

Article  CAS  PubMed  Google Scholar 

Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, Varga ZV, Varró A, Schulz R (2019) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 40:1771–1777. https://doi.org/10.1093/eurheartj/ehy365

Article  CAS  PubMed  Google Scholar 

Finke D, Heckmann MB, Salatzki J, Riffel J, Herpel E, Heinzerling LM, Meder B, Völkers M, Müller OJ, Frey N, Katus HA, Leuschner F, Kaya Z, Lehmann LH (2021) Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation. Cancers 13:2498. https://doi.org/10.3390/cancers13102498

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frodermann V, Nahrendorf M (2018) Macrophages and cardiovascular health. Physiol Rev 98:2523–2569. https://doi.org/10.1152/physrev.00068.2017

Article  CAS